Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06592014 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lithium for Parkinson's: an Extension Trial

StatusEnrolling by Invitation
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 25, 2026 (before its estimated October 1, 2026 completion). Its status may not reflect the trial's current state.
Trial flagged as At Risk
Primary completion moved at least 4 months later Jun 1, 2026 → Oct 1, 2026
See other at-risk trials from State University of New York at Buffalo

Record History

  1. Primary completion pushed from Jun 1, 2026 to Oct 1, 2026v4
  2. Primary completion date: Feb 1, 2026 to Jun 1, 2026
    • Study completion date: May 1, 2026 to Nov 1, 2026
    v3
  3. Secondary endpoints: details revised at 7 of 11 entriesv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will examine the effects of 24 weeks of lithium therapy achieving serum lithium levels of 0.25-0.50mmol/L on MRI and blood-based biomarkers in Parkinson's disease patients who have completed one of our current 24-week lithium clinical trials.
Trial Details
NCT Number NCT06592014
Lead Sponsor State University of New York at Buffalo
Conditions
(from sponsor)		 Parkinson Disease
Related terms Charcot-Marie-Tooth disease, Type 1F, Parkinson Disease
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov